Medicinalproductindication-example.json

Example of medicinalproductindication

{
  "resourceType": "MedicinalProductIndication",
  "id": "example",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: example</p><p><b>diseaseSymptomProcedure</b>: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). <span>(Details : {http://ema.europa.eu/example/indicationasdisease-symptom-procedure code 'Venousthromboembolismprophylaxis' = 'Venousthromboembolismprophylaxis)</span></p><p><b>comorbidity</b>: Hipsurgery <span>(Details : {http://ema.europa.eu/example/comorbidity code 'Hipsurgery' = 'Hipsurgery)</span></p><p><b>intendedEffect</b>: PRYLX <span>(Details : {http://ema.europa.eu/example/intendedeffect code 'PRYLX' = 'PRYLX)</span></p><p><b>population</b>: </p></div>"
  },
  "diseaseSymptomProcedure": {
    "coding": [
      {
        "system": "http://ema.europa.eu/example/indicationasdisease-symptom-procedure",
        "code": "Venousthromboembolismprophylaxis"
      }
    ],
    "text": "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip\\nor knee replacement surgery.\\nPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation\\n(NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age\\n≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).\\nTreatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent\\nDVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients)."
  },
  "comorbidity": [
    {
      "coding": [
        {
          "system": "http://ema.europa.eu/example/comorbidity",
          "code": "Hipsurgery"
        }
      ]
    }
  ],
  "intendedEffect": {
    "coding": [
      {
        "system": "http://ema.europa.eu/example/intendedeffect",
        "code": "PRYLX"
      }
    ]
  },
  "population": [
    {
      "ageRange": {
        "low": {
          "value": 18,
          "unit": "a"
        }
      }
    }
  ]
}